Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability

Alzheimer's and Dementia

Volumn 12, Issue 4, 2016, Pages 454-458

  Lim, Yen Ying ^a,b   Maruff, Paul ^b,c   Getter, Christine ^d   Snyder, Peter J ^a,d  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Cogstate Ltd ^*  (Australia)

^d RHODE ISLAND HOSPITAL   (United States)

Author keywords

Alzheimer disease; Amyloid; Amyloid beta protein; Biomarkers; Diagnosis; Disclosure; Early detection; Ethics; PET imaging; Preclinical Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FLORBETAPIR F 18; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOMUTILATION; AVOIDANCE BEHAVIOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIET; DISEASE COURSE; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HYPERAROUSAL; INSTITUTIONAL REVIEW; INTERPERSONAL COMMUNICATION; INTRUSION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEMORY; MEMORY DISORDER; MIDDLE AGED; MOOD; NEUROIMAGING; NEUROLOGIST; PATIENT SAFETY; PATIENT SATISFACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PSYCHOEDUCATION; PSYCHOLOGICAL ASPECT; PSYCHOPHYSIOLOGY; RISK FACTOR; SEMI STRUCTURED INTERVIEW; SOCIAL SUPPORT; STRESS; ADVERSE EFFECTS; BRAIN; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ETHICS; INTERVIEW; METABOLISM; PATIENT EDUCATION; PERCEPTION; PSYCHOLOGY; RISK;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; DISCLOSURE; EARLY DIAGNOSIS; ETHYLENE GLYCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PERCEPTION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK;

EID: 84961145839     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.09.005     Document Type: Article

References (23)

1. R. Au, R.J. Piers, and L. Lancashire Back to the future: Alzheimer's disease heterogeneity revisited Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 1 2015 368 370
2. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., C.H. Kawas, and et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute of Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 263 269
3. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, and et al. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study Lancet Neurol 12 2013 357 367
4. K. Uchida, L. Shan, H. Suzuki, Y. Tabuse, Y. Nishimura, Y. Hirokawa, and et al. Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 1 2015 270 280
5. N.J. Ashton, S.J. Kiddle, J. Graf, M. Ward, A.L. Baird, A. Hye, and et al. Blood protein predictors of brain amyloid for enrichment in clinical trials? The correct journal is: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. This is a different journal than 'Alzheimers Dement' 1 2015 48 60
6. J.M. Yeo, B. Waddell, Z. Khan, and S. Pal A systematic review and meta-analysis of 18 F-labeled amyloid imaging in Alzheimer's disease The correct journal is: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. This is a different journal than 'Alzheimers Dement' 1 2015 5 13
7. P.M. Doraiswamy, R.A. Sperling, K. Johnson, E.M. Reiman, T.Z. Wong, M.N. Sabbagh, and et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study Mol Psychiatry 19 2014 1044 1051
8. E.C. Mormino, R.A. Betensky, T. Hedden, A.P. Schultz, A. Ward, W. Juijbers, and et al. Amyloid and APOE E4 interact to influence short-term decline in preclinical Alzheimer's disease Neurology 82 2014 1760 1767
9. Y.Y. Lim, K.A. Ellis, R.H. Pietrzak, D. Ames, D. Darby, K. Harrington, and et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults Neurology 79 2012 1645 1652
10. G.W. Small, P. Siddarth, V. Kepe, L.M. Ercoli, A.C. Burggren, S.Y. Bookheimer, and et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau Arch Neurol 69 2012 215 222
11. R. Buckley, M.M. Saling, D. Ames, C.C. Rowe, N.T. Lautenschlager, S.L. Macauley, and et al. Factors affecting subjective memory complaints in the AIBL aging study: Biomarkers, memory, affect, and age Int Psychogeriatr 25 2013 1307 1315
12. C.A. Fyock, and B.M. Hampstead Comparing the relationship between subjective memory complaints, objective memory performance, and medial temporal lobe volumes in patients with mild cognitive impairment Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 1 2015 242 248
13. M.B. Shulman, K. Harkins, R.C. Green, and J. Karlawish Using AD biomarker research results for clinical care: A survey of ADNI investigators Neurology 81 2013 1114 1121
14. A. Leuzy, E.R. Zimmer, K. Heurling, P. Rosa-Neto, and S. Gauthier Use of amyloid PET across the spectrum of Alzheimer's disease: Clinical utility and associated ethical issues Amyloid 21 2014 143 148
15. M.M. Witte, N.L. Foster, A.S. Fleisher, M.M. Williams, K. Quaid, M. Wasserman, and et al. Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 1 2015 358 367
16. K. Harkins, P. Sankar, R. Sperling, J.D. Grill, R.C. Green, K.A. Johnson, and et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants Alzheimers Res Ther 7 2015 1 9
17. A. Koppara, M. Wagner, C. Lange, A. Ernst, B. Wiese, H.-H. König, and et al. Cognitive performance before and after the onset of subjective cognitive decline in old age The correct journal is: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. This is a different journal than 'Alzheimers Dement' 1 2015 194 205
18. Y.Y. Lim, P. Maruff, R. Schindler, B.R. Ott, Salloway, D.C. Yoo, and et al. Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease Neurobiol Aging 36 2015 2709 2715
19. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, M.A. Mintun, and et al. Use of florbetapir-PET for imaging beta-amyloid pathology J Am Med Assoc 305 2011 275 283
20. D.S. Weiss, and C.R. Marmar The impact of event scale - Revised 1997 Guilford New York
21. J.H. Lingler, and W.E. Klunk Disclosure of amyloid imaging results to research participants: Has the time come? Alzheimers Dement 9 2013 741 744
22. Sperling R, Aisen P. Anti-amyloid treatment in asymptomatic AD: A4 trial. In: Leonard Berg Symposium. St. Louis, United States of America, 2012.
23. R.C. Green, J.S. Roberts, L.A. Cupples, N.R. Relkin, P.J. Whitehouse, T. Brown, and et al. Disclosure of APOE genotype for risk of Alzheimer's disease N Engl J Med 361 2009 245 254